Cost-effectiveness analysis and prevention effects of ultra-orphan drugs for rare diseases: an in silico model applied to Cryopyrin Associated Periodic Syndromes (CAPS) by L Trieste et al.
POSTER PRESENTATION Open Access
Cost-effectiveness analysis and prevention effects
of ultra-orphan drugs for rare diseases: an in silico
model applied to Cryopyrin Associated Periodic
Syndromes (CAPS)
L Trieste1, O Della Casa Alberighi2, G Turchetti1, F Pierotti1, L Accame2, V Lorenzoni1, J Frenkel3, M Gattorno4*,
P Quartier5, A Martini4
From 8th International Congress of Familial Mediterranean Fever and Systemic Autoinflammatory Diseases
Dresden, Germany. 30 September - 3 October 2015
Objectives
This three-year, international, multicentre, longitudinal,
observational, cost-effectiveness study named RaDiCEA
(RareDisease &Cost-EffectivenessAnalysis) will assess the
economic evaluation (cost of illness - COI and cost-
effectiveness analysis - CEA) of innovative therapies (i.e.,
anti IL-1 agents), quality of life (QoL) and effects of the
prevention of otherwise irreversible central nervous sys-
tem, eye, ear, kidney, and cartilage damages of different
treatment strategies for cryopyrin-associated periodic
syndromes (CAPS) of adults and children.
Methods
A virtual time-cohort approach and a Markov model
simulating health states corresponding to different CAPS
severity will be developed to assess the cost-effectiveness
of two different treatment strategies: i.e., either anti IL-1
agents or other than anti IL-1. Due to the lack of a CAPS-
specific severity index/damage score, a linear combination
of existing indexes and damage scores will be used to rank
patient’s health status with respect to damages involving
specific organs and systems. Coefficients of the resulting
function will be assigned following both a top-down
(Delphi) and an interim-ex post-bottom-up approach
(principal component analysis) considering covariances of
all the variables adopted to describe the disease evolution
or response to therapies. The model uses relevant eco-
nomic measures to quantify resource utilization for
patients’ care in the National Health Systems’ perspectives
and a broader societal perspective to take into account
direct nonmedical costs and indirect costs, in addition to
direct costs. QoL will be evaluated using EQ-5D question-
naires. To assess how the model reacts to changes in sin-
gular and multiple disease parameters, univariate and
probabilistic sensitivity analyses will be performed.
Expected results
The RaDiCEA project will assess the long-term effec-
tiveness of different potentially life-long treatment stra-
tegies and COI, while exploring the feasibility of a new
CEA model to be generated from a rare disease (CAPS)
observational study. The economic outcomes will be
given as the number of years spent in each health state,
the related yearly costs and QoL.
Conclusions
The importance and novelty of the model is twofold:
i) in its application, adopting the cost-effectiveness
approach for assessing the impact of CAPS therapies,
and ii) in the methods, extending the analyses of the
impact of CAPS therapies in reducing the speed of dis-
ease progression.
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